Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
30.87
-0.18 (-0.58%)
At close: Dec 5, 2025, 4:00 PM EST
31.04
+0.17 (0.55%)
After-hours: Dec 5, 2025, 5:13 PM EST
Stoke Therapeutics Revenue
Stoke Therapeutics had revenue of $10.63M in the quarter ending September 30, 2025, with 117.25% growth. This brings the company's revenue in the last twelve months to $205.63M, up 1,128.17% year-over-year. In the year 2024, Stoke Therapeutics had annual revenue of $36.56M with 316.34% growth.
Revenue (ttm)
$205.63M
Revenue Growth
+1,128.17%
P/S Ratio
8.70
Revenue / Employee
$1,606,500
Employees
128
Market Cap
1.76B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
STOK News
- 1 day ago - Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting - Business Wire
- 5 days ago - Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting - Business Wire
- 17 days ago - Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
- 19 days ago - Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments - Business Wire
- 4 weeks ago - Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - Business Wire
- 4 weeks ago - Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 5 weeks ago - Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates - Business Wire
- 6 weeks ago - Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA) - Business Wire